SCHEMBL3616092

SCHEMBL3616092

O=S(=O)(O)C(Cl)c1ccc(Br)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
CA2 P00918 3/20 0.38
CA12 O43570 3/20 0.38
MMP2 P08253 3/20 0.38
CA9 Q16790 2/20 0.38
CA1 P00915 1/20 0.38
MMP1 P03956 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
CA14 Q9ULX7 2/20 0.37
PLCG1 P19174 1/20 0.35
F2 P00734 2/20 0.35
PRSS1 P07477 2/20 0.35
PRSS2 P07478 2/20 0.35
PRSS3 P35030 2/20 0.35
CNR1 P21554 2/20 0.35
CYP2C19 P33261 1/20 0.35
ALOX5 P09917 1/20 0.35
CYP2A6 P11509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31687206 0.82 CA2 (0.39) CYP1A2CA2CA12MMP2CA9
SCHEMBL4589500 0.77 SRC (0.54) CA2CA12CA9CA1CA14
SCHEMBL3134984 0.74 CYP1A2 (0.44) CYP1A2CA2CA12MMP2CA1
SCHEMBL8136959 0.74 CA2 (0.43) CA2CA12MMP2CA9CA1
Hydrochloric Acid SCHEMBL28195512 0.72 CYP1A2 (0.42) CYP1A2CA2CA12MMP2CA1
SCHEMBL29136114 0.71 PLCG1 (0.38) CYP1A2CA2CA12MMP2CA1
SCHEMBL3140883 0.69 CYP1A2 (0.40) CYP1A2MMP2MMP1MMP9MMP13
SCHEMBL20352831 0.69 CYP2A6 (0.44) CYP1A2CA2CA1CNR1CYP2C19
SCHEMBL18614894 0.68 CYP2A6 (0.50) CYP1A2CNR1CYP2C19ALOX5CYP2A6
SCHEMBL11045735 0.68 TSHR (0.50) CYP1A2CA2CA1CNR1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144681-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATION GMNB (DE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144681-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, ADORA3 CYP1A2 258/4885CA2 2235/4885CA12 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.